Literature DB >> 11872630

Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer.

Lizhong Wang1, Tomonori Habuchi, Takeshi Takahashi, Kenji Mitsumori, Toshiyuki Kamoto, Yoshiyuki Kakehi, Hideaki Kakinuma, Kazunari Sato, Akira Nakamura, Osamu Ogawa, Tetsuro Kato.   

Abstract

Cyclin D1 is believed to play an important role in the genesis and/or progression of transitional cell cancer (TCC) of the urinary bladder. Cyclin D1 gene (CCND1) mRNA is alternatively spliced to produce two transcripts, and the splicing pattern may be modulated by a G to A single nucleotide polymorphism within the splice donor site of exon 4. This study was conducted to explore the association between the polymorphism and the susceptibility to and disease status of TCC of the bladder in 222 cases and 317 native Japanese controls. The relationship between the CCND1 polymorphism and the mRNA splicing pattern in TCC cells was evaluated by semi-quantitative reverse-transcription PCR. The CCND1 A allele was more frequently observed in the TCC group than the control group (P = 0.032) with a significant difference in the genotype frequency between the two groups (P = 0.029). The AA genotype was associated with a significantly higher risk of TCC compared with the AG+GG genotypes (adjusted odds ratio (aOR) = 1.76, 95% confidence interval (CI) = 1.09-2.84, P = 0.022). This association was observed more significantly in nonsmoking cases (aOR = 2.53; 95% CI = 1.28-4.51, P = 0.008). Looking at tumor grade, the presence of the A allele was associated with higher grade (= grade 3) tumors with a gene dosage effect (aOR = 1.77, CI = 1.16-2.69, P = 0.008). In tumor stage, although not significant, the AA + AG genotypes tended to be more frequently observed in cases with T1-4 tumors than those with Ta tumors (aOR = 1.94, 95% CI = 0.98-3.82, P = 0.057). The genotype seemed to influence the two alternatively spliced forms of the CCND1 mRNA because the ratio of the CCND1 transcript-b/transcript-a was significantly higher in cases with the AA genotype compared with those with the AG + GG genotypes. These data suggest that the CCND1 variant A allele may be associated with an increased risk of TCC of the bladder, especially in men without a history of smoking, and it may also have an effect on its disease status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872630     DOI: 10.1093/carcin/23.2.257

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  26 in total

1.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

2.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

3.  Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population.

Authors:  Jing Jiang; Jingweng Wang; Sadao Suzuki; Vendhan Gajalakshmi; Kiyonori Kuriki; Yang Zhao; Seiichi Nakamura; Susumu Akasaka; Hideki Ishikawa; Shinkan Tokudome
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-03       Impact factor: 4.553

4.  Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.

Authors:  Xuwei Hou; Sili Wang; Yuling Zhou; Ziliang Xu; Yao Zou; Xiaofan Zhu; Mingzhe Han; Tianxiang Pang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

5.  Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx.

Authors:  Malgorzata Rydzanicz; Pawel Golusinski; Daniela Mielcarek-Kuchta; Wojciech Golusinski; Krzysztof Szyfter
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-29       Impact factor: 2.503

6.  Association between cyclin D1 polymorphism with CpG island promoter methylation status of tumor suppressor genes in gastric cancer.

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Masakatsu Nakamura; Hiromi Yamashita; Daisuke Yoshioka; Masaaki Okubo; Joh Yonemura; Yoshiteru Maeda; Naoko Maruyama; Toshiaki Kamano; Yoshio Kamiya; Hiroshi Fujita; Yoshihito Nakagawa; Mitsuo Nagasaka; Masami Iwata; Ichiro Hirata; Tomiyasu Arisawa
Journal:  Dig Dis Sci       Date:  2010-04-16       Impact factor: 3.199

7.  Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population.

Authors:  Mohd Nizam Zahary; Abdul Aziz Ahmad Aizat; Gurjeet Kaur; Lee Yeong Yeh; Maya Mazuwin; Ravindran Ankathil
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

8.  Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population.

Authors:  Zhangyong Hu; Zhipeng Zhou; Guolian Xiong; Yali Wang; Yi Lai; Lan Deng; Jinliang Yang
Journal:  Tumour Biol       Date:  2014-02-26

9.  Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Authors:  Clay E S Comstock; Michael A Augello; Ruth Pe Benito; Jason Karch; Thai H Tran; Fransiscus E Utama; Elizabeth A Tindall; Ying Wang; Craig J Burd; Eric M Groh; Hoa N Hoang; Graham G Giles; Gianluca Severi; Vanessa M Hayes; Brian E Henderson; Loic Le Marchand; Laurence N Kolonel; Christopher A Haiman; Raffaele Baffa; Leonard G Gomella; Erik S Knudsen; Hallgeir Rui; Susan M Henshall; Robert L Sutherland; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis.

Authors:  Changxi Zhou; Huaijie An; Mingdong Hu; Qinghui Liu; Peiliang Geng; Jiancheng Xu; Baojun Sun; Changting Liu
Journal:  Tumour Biol       Date:  2013-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.